| Symbol | ALKS |
|---|---|
| Name | ALKERMES PLC. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Pharmaceutical Preparations |
| Address | CONNAUGHT HOUSE, DUBLIN 4, L2 00000 |
| Telephone | 00-353-1-772-8000 |
| Fax | — |
| — | |
| Website | https://www.alkermes.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001520262 |
| Description | Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. Additional info from NASDAQ: |
2026-07-06 20:48
Gaffin David Joseph 🔴 sold 2.0K shares of Alkermes plc. (ALKS) at $54.03 Transaction Date: Jul 06, 2026 | Filing ID: 000105
Read more
2026-07-06 20:18
📋 Gaffin David Joseph (Officer) plans to sell 2K shares of Alkermes plc. (at $54.03 each, total $110K) Filed: Jul 06, 2026 | ID: 000311
Read more
2026-06-17 20:15
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Read more
2026-06-15 11:09
(99% Neutral) ALKERMES PLC. (ALKS) Provides Update on development for which significant unmet need remains
Read more
2026-06-15 11:00
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Read more
2026-06-13 00:04
Director Wright Christopher I 🔴 sold 2.0K shares of Alkermes plc. (ALKS) at $45.10 Transaction Date: Jun 12, 2026 | Filing ID: 000101
Read more
2026-06-12 20:19
📋 Wright Christopher I (Officer) plans to sell 2K shares of Alkermes plc. (at $45.10 each, total $90K) Filed: Jun 12, 2026 | ID: 000282
Read more
2026-06-04 21:00
Gaffin David Joseph 🔴 sold 2.0K shares of Alkermes plc. (ALKS) at $43.05 Transaction Date: Jun 04, 2026 | Filing ID: 000099
Read more
2026-06-04 20:16
📋 Gaffin David Joseph (Officer) plans to sell 2K shares of Alkermes plc. (at $43.05 each, total $88K) Filed: Jun 04, 2026 | ID: 000268
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00002316 | The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV … | Phase1 | Meningitis, Cryptococcal | Completed | — | — | ClinicalTrials.gov |
| NCT07680114 | Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizo… | Na | Schizophrenia | Not_Yet_Recruiting | 2026-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07540897 | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adult… | Phase3 | Narcolepsy Type 1 | Recruiting | 2026-06-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT07502443 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcole… | Phase3 | Narcolepsy Type 2 | Recruiting | 2026-04-22 | 2027-06-01 | ClinicalTrials.gov |
| NCT07455383 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcole… | Phase3 | Narcolepsy Type 1 | Recruiting | 2026-04-06 | 2027-06-01 | ClinicalTrials.gov |
| NCT06843590 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With … | Phase2 | Idiopathic Hypersomnia | Recruiting | 2025-05-22 | 2026-11-01 | ClinicalTrials.gov |
| NCT06555783 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With … | Phase2 | Narcolepsy Type 2 | Completed | 2024-07-26 | 2025-11-21 | ClinicalTrials.gov |
| NCT06358950 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With … | Phase2 | Narcolepsy Type 1 | Completed | 2024-03-24 | 2025-07-31 | ClinicalTrials.gov |
| NCT05662306 | C-Cog in Early Course Schizophrenia Study | Phase4 | Schizophrenia | Terminated | 2024-01-23 | 2025-03-03 | ClinicalTrials.gov |
| NCT05495984 | Neuroplasticity in Maternal Opioid Use Disorder (OUD) | Na | Opioid Use Disorder | Recruiting | 2023-01-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05547100 | Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan | Phase1 | Focus of Study is on Healthy Lactating Women | Completed | 2022-09-14 | 2022-11-19 | ClinicalTrials.gov |
| NCT05303064 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric… | Phase3 | Schizophrenia | Recruiting | 2022-06-30 | 2026-09-01 | ClinicalTrials.gov |
| NCT04928703 | Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Early_Phase1 | Healthy | Completed | 2022-05-26 | 2022-12-12 | ClinicalTrials.gov |
| NCT04987229 | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | Phase3 | Bipolar I Disorder | Enrolling_By_Invitation | 2021-10-22 | 2027-09-01 | ClinicalTrials.gov |
| NCT04987658 | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder | Phase1 | Bipolar I Disorder | Completed | 2021-07-22 | 2023-08-11 | ClinicalTrials.gov |
| NCT04576507 | Repeated Cannabis Administration on Experimental Pain and Abuse Liability | Phase2 | Cannabis | Completed | 2021-06-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04203056 | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizop… | Phase4 | Schizophrenia | Terminated | 2019-12-16 | 2022-10-01 | ClinicalTrials.gov |
| NCT04025502 | Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Hea… | — | Schizophrenia | Completed | 2019-10-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT03963973 | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 | Phase1 | Healthy | Terminated | 2019-05-16 | 2020-01-22 | ClinicalTrials.gov |
| NCT03919994 | Observational Study of Long Acting Injectable Medications (LAIs) in Schizophren… | — | Schizophrenia | Completed | 2019-03-28 | 2023-01-04 | ClinicalTrials.gov |
| NCT03711318 | Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent In… | Phase3 | Heroin Dependence | Terminated | 2018-11-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03610048 | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive … | Phase3 | Refractory Major Depressive Disorder | Terminated | 2018-08-09 | 2020-05-01 | ClinicalTrials.gov |
| NCT03345979 | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of… | Phase3 | Schizophrenia | Completed | 2017-11-15 | 2019-03-12 | ClinicalTrials.gov |
| NCT03187769 | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who … | Phase3 | Schizophrenia | Completed | 2017-06-08 | 2022-01-03 | ClinicalTrials.gov |
| NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-03-15 | 2019-06-27 | ClinicalTrials.gov |
| NCT02922426 | An Insulin Sensitivity Study in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2016-09-01 | 2017-07-20 | ClinicalTrials.gov |
| NCT02873208 | A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With … | Phase3 | Schizophrenia | Completed | 2016-08-07 | 2019-10-17 | ClinicalTrials.gov |
| NCT02804568 | A Phase 1 Safety Study in Adults With Schizophrenia | Phase1 | Schizophrenia | Completed | 2016-06-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02696434 | Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With … | Phase3 | Opioid Use Disorder | Completed | 2016-04-01 | 2017-11-30 | ClinicalTrials.gov |
| NCT02694328 | A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) | Phase3 | Schizophrenia | Completed | 2016-03-02 | 2018-11-07 | ClinicalTrials.gov |
| NCT02669758 | A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophr… | Phase3 | Schizophrenia | Completed | 2016-01-20 | 2018-06-29 | ClinicalTrials.gov |
| NCT02634307 | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS)… | Phase3 | Multiple Sclerosis | Completed | 2015-12-10 | 2021-11-11 | ClinicalTrials.gov |
| NCT02634346 | A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the EN… | Phase3 | Schizophrenia | Completed | 2015-12-01 | 2017-06-07 | ClinicalTrials.gov |
| NCT02634320 | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With S… | Phase4 | Schizophrenia | Completed | 2015-12-01 | 2017-07-11 | ClinicalTrials.gov |
| NCT02636842 | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffect… | Phase1 | Schizophrenia | Completed | 2015-12-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02537574 | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use … | Phase3 | Opioid Use Disorder | Completed | 2015-08-01 | 2017-01-09 | ClinicalTrials.gov |
| NCT02508506 | Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and … | Phase1 | Renal Impairment | Completed | 2015-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02521857 | A Water Consumption Study of ALKS 5461 in Healthy Volunteers | Phase1 | Healthy | Completed | 2015-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02504463 | A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers | Phase1 | Healthy | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02110264 | Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) | Phase3 | Opioid Use Disorders | Completed | 2015-06-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT02452801 | Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With … | Phase1 | Hepatic Impairment | Completed | 2015-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02272764 | A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers | Phase1 | Pharmacokinetics | Completed | 2014-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02218021 | A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Depende… | Phase1 | Healthy Volunteers | Completed | 2014-08-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02218008 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FOR… | Phase3 | Major Depressive Disorder | Completed | 2014-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02161718 | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder | Phase2 | Schizophrenia | Completed | 2014-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02158546 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the… | Phase3 | Major Depressive Disorder | Completed | 2014-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02141399 | A Long-Term Safety Study of ALKS 5461 | Phase3 | Major Depressive Disorder | Completed | 2014-05-01 | 2017-11-20 | ClinicalTrials.gov |
| NCT02085135 | A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depr… | Phase3 | Major Depressive Disorder | Completed | 2014-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02068105 | A Study of ALKS 5461 in Healthy Volunteers | Phase1 | Pharmacokinetics | Completed | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01932801 | Harm Reduction With Pharmacotherapy (HaRP) | Phase2 | Alcohol Use Disorder | Completed | 2013-08-01 | 2019-06-30 | ClinicalTrials.gov |
| NCT01895452 | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | Phase3 | Schizophrenia | Completed | 2013-07-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01690546 | Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Depe… | Phase2 | Opiate Dependence | Completed | 2012-09-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01449565 | Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have… | Phase2 | Amphetamine-Related Disorders | Completed | 2012-09-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01626456 | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | Phase3 | Schizophrenia | Completed | 2012-06-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01493726 | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia | Phase1 | Schizophrenia | Completed | 2011-12-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01469039 | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripipr… | Phase3 | Schizophrenia | Completed | 2011-12-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01500200 | A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) | Phase2 | Major Depressive Disorder | Completed | 2011-12-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01436032 | Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal La… | Phase3 | Laparoscopic Surgery | Terminated | 2011-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01418092 | ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults Wi… | Phase2 | OIC | Completed | 2011-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01366001 | ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Al… | Phase1 | Cocaine Abuse | Completed | 2011-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01422837 | ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry | — | Opioid Dependence | Completed | 2011-08-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01382797 | ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipa… | Phase2 | Opioid-induced Constipation | Completed | 2011-08-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01381107 | ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administ… | Phase1 | Major Depressive Disorder | Completed | 2011-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01453374 | A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration | Phase4 | Opioid Dependence | Completed | 2011-01-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01098435 | ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2010-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01180647 | Extended-Release Naltrexone for Opioid Relapse Prevention Following Release Fro… | Phase3 | Opiate Dependence | Completed | 2010-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01100151 | ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipa… | Phase2 | Opioid-induced Constipation | Completed | 2010-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00981617 | ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence | Phase2 | Alcohol Dependence | Completed | 2009-10-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00945763 | Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impacti… | Phase2 | Dental Pain | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00777062 | VIVITROL as a Treatment for Cocaine and Alcohol Dependence | Phase2 | Cocaine Dependence | Completed | 2009-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00834080 | ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to H… | Phase3 | Opiate Dependence | Completed | 2009-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00801684 | ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects… | Phase2 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2009-02-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00800319 | ALK33-001: A Study of RDC-0313 Administered to Healthy Adults | Phase1 | Alcohol Dependence | Completed | 2008-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01246765 | National Pregnancy Registry for Psychiatric Medications | — | Pregnant Women | Recruiting | 2008-11-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT00802035 | ALK29-002: A Study of Baclofen Formulations in Healthy Adults | Phase1 | Alcohol Dependence | Completed | 2008-11-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00678418 | ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults Wi… | Phase3 | Opiate Dependence | Completed | 2008-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00490854 | A Study for Patients With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-07-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00501631 | ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforc… | Phase3 | Alcohol Dependence | Completed | 2007-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00465959 | Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Ob… | Phase1 | Chronic Obstructive Pulmonary Disease | Completed | 2007-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00447213 | A Study for Patients With Type 1 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00437112 | Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients Wi… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2007-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00391209 | Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Me… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00355849 | Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00356109 | Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes | Phase3 | Diabetes Mellitus, Type 1 | Completed | 2006-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00325364 | Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00157339 | Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or … | Phase3 | Diabetes Mellitus | Completed | 2005-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00127634 | Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes | Phase3 | Diabetes Mellitus, Type 1 | Completed | 2005-07-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00099515 | Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00156936 | ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- … | Phase3 | Alcoholism | Terminated | 2004-08-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00156923 | ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-depe… | Phase3 | Alcoholism | Completed | 2003-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01218997 | ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) | Phase3 | Alcoholism | Completed | 2003-08-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00063128 | Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 … | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2003-04-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT01218971 | ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-te… | Phase3 | Alcohol Dependence | Completed | 2002-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT01218984 | ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in … | Phase2 | Opiate Dependence | Completed | 2002-03-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT01218958 | ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults | Phase3 | Alcoholism | Completed | 2002-02-01 | 2003-09-01 | ClinicalTrials.gov |
Total clinical trials: 95
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham TES-TI | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07680114 |
| TES-TI | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07680114 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Sham TES-TI | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07680114 |
| TES-TI | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07680114 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| ALKS 2680 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT06358950 |
| ALKS 2680 | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT06358950 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| OLZ/SAM | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| OLZ/SAM | Other | Phase PHASE3 | Bipolar I Disorder | ENROLLING_BY_INVITATION | NCT04987229 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Amphotericin B | Other | Phase PHASE1 | Meningitis, Cryptococcal | COMPLETED | NCT00002316 |
| Lobradimil | Other | Phase PHASE1 | Meningitis, Cryptococcal | COMPLETED | NCT00002316 |
| Amphotericin B | Other | Phase PHASE1 | Meningitis, Cryptococcal | COMPLETED | NCT00002316 |
| Lobradimil | Other | Phase PHASE1 | Meningitis, Cryptococcal | COMPLETED | NCT00002316 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Oral naltrexone to Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | TERMINATED | NCT00156936 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | TERMINATED | NCT00156936 |
| Oral naltrexone to Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | TERMINATED | NCT00156936 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | TERMINATED | NCT00156936 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT01218971 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT01218971 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT01218971 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT01218971 |
| Oral naltrexone 50 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218997 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218997 |
| Oral naltrexone 50 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218997 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218997 |
| TrIP-2SS + Foradil | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| TrIP-2SS | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| TrIP-2D | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| TrIP-2SS + Foradil | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| TrIP-2SS | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| TrIP-2D | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00801684 |
| Motrin | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| placebo | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| N1539 | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| Motrin | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| placebo | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| N1539 | Other | Phase PHASE2 | Dental Pain | COMPLETED | NCT00945763 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00800319 |
| RDC-0313 | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00800319 |
| Placebo | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00800319 |
| RDC-0313 | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00800319 |
| Placebo | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT01381107 |
| ALKS 5461 | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT01381107 |
| Placebo | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT01381107 |
| ALKS 5461 | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT01381107 |
| Placebo | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01100151 |
| RDC-1036 (ALKS 37) | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01100151 |
| Placebo | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01100151 |
| RDC-1036 (ALKS 37) | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01100151 |
| Placebo | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01098435 |
| RDC-0313 (ALKS 33) | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01098435 |
| Placebo | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01098435 |
| RDC-0313 (ALKS 33) | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01098435 |
| Placebo | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (10 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (2.5 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (1 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| Placebo | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (10 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (2.5 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| ALKS33 (RDC-0313) (1 mg) | Other | Phase PHASE2 | Alcohol Dependence | COMPLETED | NCT00981617 |
| Baclofen ER | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00802035 |
| Baclofen IR | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00802035 |
| Baclofen ER | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00802035 |
| Baclofen IR | Other | Phase PHASE1 | Alcohol Dependence | COMPLETED | NCT00802035 |
| Placebo for VIVITROL 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT00501631 |
| VIVITROL 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT00501631 |
| Placebo for VIVITROL 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT00501631 |
| VIVITROL 380 mg | Other | Phase PHASE3 | Alcohol Dependence | COMPLETED | NCT00501631 |
| Placebo | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| Ketorolac Tromethamine | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| N1539 | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33 | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33-BUP | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| Placebo | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33 | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33-BUP | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| Placebo | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33 | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| ALKS 33-BUP | Other | Phase PHASE1 | Cocaine Abuse | COMPLETED | NCT01366001 |
| Placebo | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| Ketorolac Tromethamine | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| N1539 | Other | Phase PHASE3 | Laparoscopic Surgery | TERMINATED | NCT01436032 |
| Placebo | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01382797 |
| ALKS 37 | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01382797 |
| Placebo | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01382797 |
| ALKS 37 | Other | Phase PHASE2 | Opioid-induced Constipation | COMPLETED | NCT01382797 |
| Placebo | Other | Phase PHASE2 | OIC | COMPLETED | NCT01418092 |
| ALKS 37 | Other | Phase PHASE2 | OIC | COMPLETED | NCT01418092 |
| Placebo | Other | Phase PHASE2 | OIC | COMPLETED | NCT01418092 |
| ALKS 37 | Other | Phase PHASE2 | OIC | COMPLETED | NCT01418092 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02068105 |
| ALKS 5461 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02068105 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02068105 |
| ALKS 5461 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02068105 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| trospium chloride inhalation powder (TrIP) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| trospium chloride inhalation powder (TrIP) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| trospium chloride inhalation powder (TrIP) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| trospium chloride inhalation powder (TrIP) | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00465959 |
| Placebo | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00678418 |
| VIVITROL® 380 mg | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00678418 |
| Placebo | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00678418 |
| VIVITROL® 380 mg | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00678418 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT02634320 |
| PBO-N/PBO-B | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| NTX/PBO-B | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| NTX/BUP | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| PBO-N/PBO-B | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| NTX/PBO-B | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| NTX/BUP | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02537574 |
| Oxycodone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Samidorphan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Oxycodone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Samidorphan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Oxycodone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| Samidorphan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02218021 |
| ALKS 5461 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02272764 |
| Itraconazole | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02272764 |
| ALKS 5461 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02272764 |
| Itraconazole | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02272764 |
| VIVITROL 380mg | Other | Phase PHASE4 | Opioid Dependence | COMPLETED | NCT01453374 |
| VIVITROL 380mg | Other | Phase PHASE4 | Opioid Dependence | COMPLETED | NCT01453374 |
| [14c]-Samidorphan oral | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| [14c]-Samidorphan sublingual | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| Samidorphan IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| [14c]-Samidorphan oral | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| [14c]-Samidorphan sublingual | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| Samidorphan IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| [14c]-Samidorphan oral | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| [14c]-Samidorphan sublingual | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| Samidorphan IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02504463 |
| ALKS 5461 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02521857 |
| ALKS 5461 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02521857 |
| ALKS 5461 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02508506 |
| ALKS 5461 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02508506 |
| ALKS 5461 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02508506 |
| ALKS 5461 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT02452801 |
| ALKS 5461 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT02452801 |
| Motivational Enhancement Counseling | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT01180647 |
| Extended-Release Naltrexone | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT01180647 |
| Motivational Enhancement Counseling | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT01180647 |
| Extended-Release Naltrexone | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT01180647 |
| Placebo | Other | Phase PHASE2 | Amphetamine-Related Disorders | COMPLETED | NCT01449565 |
| Naltrexone | Other | Phase PHASE2 | Amphetamine-Related Disorders | COMPLETED | NCT01449565 |
| Placebo | Other | Phase PHASE2 | Amphetamine-Related Disorders | COMPLETED | NCT01449565 |
| Naltrexone | Other | Phase PHASE2 | Amphetamine-Related Disorders | COMPLETED | NCT01449565 |
| buprenorphine/naloxone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| extended release naltrexone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| very low dose naltrexone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| buprenorphine/naloxone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| extended release naltrexone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| very low dose naltrexone | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01690546 |
| Aripiprazole Lauroxil | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02636842 |
| Aripiprazole Lauroxil | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02636842 |
| ALKS 3831 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02804568 |
| ALKS 3831 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02804568 |
| Naloxone Challenge and Oral Naltrexone Tolerability Testing | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Hydromorphone (10 mg/mL) | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 300 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 150 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 75 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Naloxone Challenge and Oral Naltrexone Tolerability Testing | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Hydromorphone (10 mg/mL) | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 300 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 150 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Medisorb naltrexone 75 mg | Other | Phase PHASE2 | Opiate Dependence | COMPLETED | NCT01218984 |
| Placebo matching Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Placebo matching Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Placebo matching Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Placebo matching Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT01218958 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT00156923 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT00156923 |
| Medisorb naltrexone 190 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT00156923 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Alcoholism | COMPLETED | NCT00156923 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| Olanzapine | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| ALKS 3831 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| Olanzapine | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| ALKS 3831 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02922426 |
| ALKS 9072, High Dose | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01895452 |
| ALKS 9072, Low Dose | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01895452 |
| ALKS 9072, High Dose | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01895452 |
| ALKS 9072, Low Dose | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01895452 |
| Placebo | Other | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00777062 |
| VIVITROL (Naltrexone extended-release injectable suspension) | Other | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00777062 |
| Placebo | Other | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00777062 |
| VIVITROL (Naltrexone extended-release injectable suspension) | Other | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00777062 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| ALK3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| ALK3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| ALK3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02634346 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, High dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, Med dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, Low dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, High dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, Med dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, Low dose | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01493726 |
| ALKS 9072, High | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| ALKS 9072, Low | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| ALKS 9072, High | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| ALKS 9072, Low | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| ALKS 9072, High | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| ALKS 9072, Low | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01626456 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT02634320 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT02634320 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00834080 |
| Medisorb naltrexone 380 mg | Other | Phase PHASE3 | Opiate Dependence | COMPLETED | NCT00834080 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02141399 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02141399 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02141399 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01469039 |
| ALKS 9072 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01469039 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01469039 |
| ALKS 9072 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01469039 |
| Buprenorphine | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Placebo | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Naltrexone | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Buprenorphine | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Placebo | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Naltrexone | Other | Phase PHASE3 | Opioid Use Disorder | COMPLETED | NCT02696434 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01500200 |
| ALKS 5461 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01500200 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01500200 |
| ALKS 5461 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01500200 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02158546 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02158546 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02158546 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02158546 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02669758 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02669758 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02218008 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02218008 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02218008 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02218008 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02085135 |
| ALKS 5461 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02085135 |
| ETAU | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| XR-NTX+PN | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| XR-NTX | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| ETAU | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| XR-NTX+PN | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| XR-NTX | Other | Phase PHASE3 | Opioid Use Disorders | COMPLETED | NCT02110264 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02694328 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02694328 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02694328 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02694328 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| RDN-929 oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| RDN-929 oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| RDN-929 oral capsule | Other | Phase PHASE1 | Healthy | TERMINATED | NCT03963973 |
| Paliperidone Palmitate | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03345979 |
| Aripiprazole Lauroxil | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03345979 |
| Paliperidone Palmitate | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03345979 |
| Aripiprazole Lauroxil | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03345979 |
| ALKS 5461 | Other | Phase PHASE3 | Refractory Major Depressive Disorder | TERMINATED | NCT03610048 |
| ALKS 5461 | Other | Phase PHASE3 | Refractory Major Depressive Disorder | TERMINATED | NCT03610048 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02873208 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT02873208 |
| Placebo + olanzapine | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02161718 |
| Samidorphan + olanzapine (ALKS 3831) | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02161718 |
| Placebo + olanzapine | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02161718 |
| Samidorphan + olanzapine (ALKS 3831) | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02161718 |
| Buprenorphine/naloxone | Other | Phase PHASE3 | Heroin Dependence | TERMINATED | NCT03711318 |
| Buprenorphine/naloxone | Other | Phase PHASE3 | Heroin Dependence | TERMINATED | NCT03711318 |
| Buprenorphine/naloxone | Other | Phase PHASE3 | Heroin Dependence | TERMINATED | NCT03711318 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03187769 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03187769 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03187769 |
| ALKS 3831 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03187769 |
| LYBALVI | Other | Phase PHASE1 | Focus of Study is on Healthy Lactating Women | COMPLETED | NCT05547100 |
| LYBALVI | Other | Phase PHASE1 | Focus of Study is on Healthy Lactating Women | COMPLETED | NCT05547100 |
| HRC | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| Placebo | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| XR-NTX | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| HRC | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| Placebo | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| XR-NTX | Other | Phase PHASE2 | Alcohol Use Disorder | COMPLETED | NCT01932801 |
| OLZ/SAM | Other | Phase PHASE1 | Bipolar I Disorder | COMPLETED | NCT04987658 |
| OLZ/SAM | Other | Phase PHASE1 | Bipolar I Disorder | COMPLETED | NCT04987658 |
| OLZ/SAM | Other | Phase PHASE1 | Bipolar I Disorder | COMPLETED | NCT04987658 |
| AL-NCD | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| ARI-ORAL | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| AL-NCD | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| ARI-ORAL | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT04203056 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| OLZ/SAM | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| OLZ/SAM | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT05303064 |
| Placebo Cannabis | Other | Phase PHASE2 | Cannabis | COMPLETED | NCT04576507 |
| Active Cannabis | Other | Phase PHASE2 | Cannabis | COMPLETED | NCT04576507 |
| Placebo Cannabis | Other | Phase PHASE2 | Cannabis | COMPLETED | NCT04576507 |
| Active Cannabis | Other | Phase PHASE2 | Cannabis | COMPLETED | NCT04576507 |
| MIO | Other | Approved | Opioid Use Disorder | RECRUITING | NCT05495984 |
| ERPs with electroencephalography (EEG) | Other | Approved | Opioid Use Disorder | RECRUITING | NCT05495984 |
| MIO | Other | Approved | Opioid Use Disorder | RECRUITING | NCT05495984 |
| ERPs with electroencephalography (EEG) | Other | Approved | Opioid Use Disorder | RECRUITING | NCT05495984 |
| Computerized cognitive and functional skills training | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Computerized cognitive and functional skills training | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Computerized cognitive and functional skills training | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Aripiprazole Lauroxil | Other | Phase PHASE4 | Schizophrenia | TERMINATED | NCT05662306 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| ALKS 2680 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| ALKS 2680 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| ALKS 2680 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06843590 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT06555783 |
| ALKS 2680 | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT06555783 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT06555783 |
| ALKS 2680 | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT06555783 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | NOT_YET_RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | NOT_YET_RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | NOT_YET_RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | NOT_YET_RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07540897 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 3 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 2 | RECRUITING | NCT07502443 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 2 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
| ALKS 2680 Dose 1 | Other | Phase PHASE3 | Narcolepsy Type 1 | RECRUITING | NCT07455383 |
Total products: 496